Crescent Biopharma, Inc. (CBIO)

17.75 -0.06% (-0.01)

Over 5Y: -90.3%

2026-08-28
200 400
2021 2022 2023 2024 2025 2026

Financials Quarterly

Q3 '21 — Revenue: 86.6K Q3 '21 — Operating Cash Flow: -16.9M Q3 '21 — Free Cash Flow: -17M Q3 '21 — Net Income: -17.3M Q4 '21 — Revenue: 17.6K Q4 '21 — Operating Cash Flow: -12.8M Q4 '21 — Free Cash Flow: -12.8M Q4 '21 — Net Income: -17.4M Q1 '22 — Revenue: 0 Q1 '22 — Operating Cash Flow: -13.7M Q1 '22 — Free Cash Flow: -13.7M Q1 '22 — Net Income: -14.7M Q2 '22 — Revenue: 75K Q2 '22 — Operating Cash Flow: -16.2M Q2 '22 — Free Cash Flow: -16.3M Q2 '22 — Net Income: -13.3M Q3 '22 — Revenue: 0 Q3 '22 — Operating Cash Flow: -8.6M Q3 '22 — Free Cash Flow: -8.6M Q3 '22 — Net Income: -8.5M Q4 '22 — Revenue: 0 Q4 '22 — Operating Cash Flow: -7.9M Q4 '22 — Free Cash Flow: -7.9M Q4 '22 — Net Income: -10.2M Q1 '23 — Operating Cash Flow: -11.6M Q1 '23 — Free Cash Flow: -11.6M Q1 '23 — Net Income: -10.4M Q2 '23 — Operating Cash Flow: -7M Q2 '23 — Free Cash Flow: -7M Q2 '23 — Net Income: -8.3M Q3 '23 — Operating Cash Flow: -8.7M Q3 '23 — Free Cash Flow: -8.7M Q3 '23 — Net Income: -9.2M Q4 '23 — Operating Cash Flow: -7.6M Q4 '23 — Free Cash Flow: -7.6M Q4 '23 — Net Income: -9.1M Q1 '24 — Operating Cash Flow: -10.5M Q1 '24 — Free Cash Flow: -10.5M Q1 '24 — Net Income: -10.7M Q2 '24 — Operating Cash Flow: -8.9M Q2 '24 — Free Cash Flow: -8.9M Q2 '24 — Net Income: -10.1M Q3 '24 — Operating Cash Flow: -8M Q3 '24 — Free Cash Flow: -8M Q3 '24 — Net Income: -9.8M Q4 '24 — Operating Cash Flow: -6.3M Q4 '24 — Free Cash Flow: -6.3M Q4 '24 — Net Income: -15.2M Q1 '25 — Revenue: 0 Q1 '25 — Operating Cash Flow: -10.9M Q1 '25 — Free Cash Flow: -10.9M Q1 '25 — Net Income: -15.1M Q2 '25 — Revenue: 0 Q2 '25 — Operating Cash Flow: -16.4M Q2 '25 — Free Cash Flow: -16.5M Q2 '25 — Net Income: -21.8M Q3 '25 — Operating Cash Flow: -17.5M Q3 '25 — Free Cash Flow: -18.1M Q3 '25 — Net Income: -24.6M Q4 '25 — Operating Cash Flow: -26.7M Q4 '25 — Free Cash Flow: -26.9M Q4 '25 — Net Income: -23.3M Q1 '26 — Revenue: 1M Q1 '26 — Operating Cash Flow: -8.9M Q1 '26 — Free Cash Flow: -9.1M Q1 '26 — Net Income: -23.3M Q2 '26 — Revenue: 0 Q2 '26 — Operating Cash Flow: -19.5M Q2 '26 — Free Cash Flow: -19.5M Q2 '26 — Net Income: -24.8M -24M -18M -12M -6M 0 6M
Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2025-12-31, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 136.6%
OE margin -815.4%
Oper. margin -1553.6%
Accruals -12.8%
Asset turnover 0.059×
EBITDA margin -1551.6%
FCF margin -678.9%
OCF margin -670.2%
Profit margin -885.5%
ROA -52.5%
ROCE -102.6%
ROE -58.8%
Gross margin —
OCF / EBIT —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

3.5
RPO / sales 0.29×
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

7.2
Current ratio 11.6×
ND/EBITDA —
Cash runway 2.3 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 9.7×
F-score 5.1 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

4.1
Sales Q/Q -100.0%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales/sh Y/Y —

3 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.